Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines
Authors:
- Claudia Lanvers-KaminskyCLClaudia Lanvers-Kaminsky
- Alexis BremerABAlexis Bremer
- Uta DirksenUDUta Dirksen
- Heribert JürgensHJHeribert Jürgens
- Joachim BoosJBJoachim Boos
- 1 July 2006
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 17 (6) , 657-662
Abstract
High-dose chemotherapy of solid tumors aims at eliminating residual or metastatic tumor cells, which remained after conventional treatment. Thus, anticancer drugs used for high-dose chemotherapy should display significant cytotoxicity against the respective tumors. As little data are available about the in-vitro toxicity of busulfan and treosulfan especially on pediatric tumor cell lines, we compared the cytotoxicity of treosulfan and busulfan on four Ewing tumor, four neuroblastoma, two osteosarcoma and two leukemia cell lines in vitro. Growth inhibition of tumor cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide test after 24, 48, 72 and 96 h. Treosulfan and busulfan reduced the growth of all tumor cell lines in a time-dependent and dose-dependent manner. In vitro treosulfan was consistently more cytotoxic than busulfan. Fifty percent growth inhibitions of 608–0.73 μmol/l were determined for treosulfan and of above 5000–2.81 μmol/l for busulfan. Both drugs exhibited similar cytotoxicity profiles. Busulfan-sensitive/resistant cell lines were also sensitive/resistant to treosulfan. Overall, the leukemia cell lines were most sensitive to busulfan and treosulfan. The Ewing tumor cell lines were the second most sensitive followed by the neuroblastoma cell lines. The osteosarcoma cell lines were the most resistant cell lines. Although the in-vitro stability of both drugs makes direct comparison of their in-vitro toxicity difficult and does not allow any estimation of dosages needed clinically, the in-vitro results indicate substantial cytotoxicity of both drugs on leukemias, Ewing tumors and neuroblastomas. These data suggest further evaluation of treosulfan for high-dose chemotherapy of advanced Ewing tumors, neuroblastomas and high-risk leukemias.Keywords
This publication has 31 references indexed in Scilit:
- Treatment of Ewing sarcoma family of tumors: Current status and outlook for the futureMedical and Pediatric Oncology, 2003
- High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT)Critical Reviews in Oncology/Hematology, 2002
- DNA alkylation and interstrand cross-linking by treosulfanBritish Journal of Cancer, 1998
- 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusionsEuropean Journal of Cancer, 1997
- Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by In vitro mafosfamide-Purged autologous bone marrow transplantationEuropean Journal of Cancer, 1997
- Autologous stem cell transplantation for solid tumors in childrenCurrent Opinion in Pediatrics, 1997
- 4-Methanesulfonyloxybutanol: Hydrolysis of BusulfanJournal of Pharmaceutical Sciences, 1973
- Epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. Preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonateJournal of Medicinal Chemistry, 1970
- Alkylating Agents Related to 2,2′-Biaziridine. I. Compounds Derived from 1,4-Diamino-2,3-butanediolJournal of Medicinal Chemistry, 1967
- Stereoisomere 1,4-Di-O-methansulfonyl-butan-1,2,3,4-tetroleTetrahedron Letters, 1961